DexCom击败了Q2收入,但未能获得全年指导,导致其库存下降,尽管收效显著。 DexCom beat Q2 earnings but fell short on full-year guidance, causing its stock to dip despite strong results.

DexCom(DXCM)报告,2025年Q2收入强劲,有61美元EPS和12.1亿美元收入,超过估计,但公司2025年全年收入预测后股票下跌,低于预期。 DexCom (DXCM) reported strong Q2 2025 earnings with $0.61 EPS and $1.21 billion in revenue, surpassing estimates, but its stock dipped after the company’s full-year 2025 revenue forecast fell short of expectations. 2025年11月3日的股票交易额为58.22美元,仍低于52周最高值的24.2%,接近55.31至61.13美元的关键历史支持范围,以前曾回升过。 The stock, trading at $58.22 on November 3, 2025, remains 24.2% below its 52-week high and is near a key historical support range of $55.31 to $61.13, where it has previously rebounded. 尽管年均下降16.8%, 分析师仍维持“机动购买”评分, 目标为91.65美元。 Despite a 16.8% year-to-date decline, analysts maintain a "Moderate Buy" rating with a $91.65 target.